
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Q I have a patient, a 9-year-old boy, whose family recently moved to a new neighborhood. Every morning since the boy started attending his new school, he has complained of nausea and had at least one episode of emesis, either before leaving for school or on the way there.






